Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Non-Current Assets (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Non-Current Assets for 8 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 79.88% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, down 78.75% year-over-year, with the annual reading at $1.8 million for FY2025, 79.88% down from the prior year.
  • Non-Current Assets for Q4 2025 was $1.8 million at Whitehawk Therapeutics, down from $2.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $9.0 million in Q4 2024, with the low at $29452.0 in Q2 2021.
  • Average Non-Current Assets over 5 years is $5.1 million, with a median of $6.0 million recorded in 2023.
  • The sharpest move saw Non-Current Assets crashed 89.52% in 2021, then skyrocketed 14503.42% in 2022.
  • Over 5 years, Non-Current Assets stood at $6.6 million in 2021, then plummeted by 36.61% to $4.2 million in 2022, then soared by 86.24% to $7.8 million in 2023, then grew by 15.25% to $9.0 million in 2024, then tumbled by 79.88% to $1.8 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $1.8 million, $2.0 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.